Skip to content
Log in
Sponsored AI AM CLAUDE, A Beginner's Guide: Learn the basics of working with AI AI AM CLAUDE, A Beginner's Guide: Learn the basics of working with AI

Author

Jianfeng Zhou

h-index 14 View on Semantic Scholar

We have 6 of 62 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

The role of adjuvant therapy in non-pCR patients after neoadjuvant chemoimmunotherapy: Comparison with neoadjuvant chemoradiotherapy for ESCC.

BACKGROUND Neoadjuvant chemoimmunotherapy (NCIT) is increasingly used for locally advanced esophageal squamous cell carcinoma (ESCC), but the role of adjuvant therapy-particularly immunotherapy-after NCIT remains undefined. METHODS This single-institution retrospective study included 458 ESCC patients treated with ne...

Yu-Hao Peng, Xin Xiao, Pin-Hao Fang et al. · 0 citations
Aug 2026

PD01.07. Surgery Timing After Neoadjuvant Therapy for Esophageal Carcinoma: A Meta-Analysis of 7,544 Patients

While delayed surgery after neoadjuvant therapy in esophageal carcinoma patients may be associated with a higher risk of anastomotic leaks and a lower rate of R0 resection, its impact on long-term survival remains an area of ongoing investigation.

Jian-Feng Zhou, Pin-Hao Fang, Yong Yuan et al. · 0 citations
Aug 2026

P1.080. Dynamic ctDNA Profiling Predicts Pathological Complete Response and Identifies Pseudoprogression in ESCC Receiving Neoadjuvant Immunochemotherapy

Esophageal Cancer: Adjuvant and Neo-Adjuvant Therapies The integration of anti-PD-1 antibody therapy with chemotherapy has shown promising results in the neoadjuvant treatment of locally advanced esophageal squamous cell carcinoma. Conventional imaging may not fully capture immunotherapy effects due to unc...

Jian-Feng Zhou, Yu-Shang Yang, Yong Yuan et al. · 0 citations
Open access Jul 2026

Causal immune-inflammation mapping of the GERD-Barrett-adenocarcinoma cascade identifies FGF19-HLA-DR⁺ T-cell axis driving esophagogastric junction metaplasia.

BACKGROUND Gastroesophageal reflux disease (GERD), Barrett's esophagus (BE), and esophageal adenocarcinoma (EAC) form a recognized pathological continuum, but the causal immune and inflammatory processes driving progression remain incompletely defined. METHODS Summary-level genome-wide association study (GWAS) data w...

Yixin Liu, Zhipeng Gong, Yuwen Tan et al. · 0 citations
Jul 2026

Single-Cell Analysis of Residual Esophageal Squamous Cell Carcinoma After Neoadjuvant Immunochemotherapy Reveals TFAM-Mediated Immunoregulation in Dendritic Cells.

The TME in residual ESCC after nICT is characterized and revealed an association between elevated TFAM expression in DCs and poor responsiveness to nICT, indicating the critical role of TFAM deficiency in DCs in activating anti-tumor immunity.

Linyan Chen, Tang Feng, Jian-Feng Zhou et al. · 1 citation
Aug 2026

P1.003. Causal Immune-Inflammation Mapping of the GERD-Barrett-Adenocarcinoma Cascade Identifies FGF19-HLA-DR+ T-Cell Axis Driving Esophagogastric Junction Metaplasia

FGF19 emerges as a key cytokine driving EGJ glandular remodeling through HLA-DR+ CD4+/CD8+ T-cell associated immune activation, providing candidate molecular targets for early prevention and intervention.

Yixin Liu, Jian-Feng Zhou, Yu-Shang Yang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.